Real-World Data Show Minimal Weight Regain After Stopping GLP-1 Obesity Drugs
A Cleveland Clinic study of nearly 8,000 adults who stopped GLP-1 medications (such as Ozempic or tirzepatide) found only modest weight regain after one year (average 0.5%), suggesting real-world outcomes may diverge from clinical trials. Many patients either stay on some form of obesity treatment or switch to alternatives, with weight loss largely maintained when ongoing care and lifestyle support are in place, though results vary across populations and settings.